BCL2 and cancer: Deletions or inactivating mutations of Bax or Bak are uncommon, but many cancers that are resistant to treatment, including leukemia, gastric, and colon cancers, can demonstrate increased expression of pro-survival molecules such as Bcl-2 and Bcl-xL [47-49].